A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer-Reference-Cited by-同舟云学术

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

Published:2018-09-05 Issue:1 Volume:20 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Schöffski Patrick,Cresta Sara,Mayer Ingrid A.,Wildiers Hans,Damian Silvia,Gendreau Steven,Rooney Isabelle,Morrissey Kari M.,Spoerke Jill M.,Ng Vivian W.,Singel Stina M.,Winer Eric

Funder

Genentech Inc. / F.Hoffmann-La Roche Ltd.

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13058-018-1015-x.pdf

Reference43 articles.

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer. Version 2. 2016. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf . Accessed 14 Oct 2016.

2. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, et al. ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2). Breast. 2014;23(5):489–502.

3. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–76.

4. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27(41):5497–510.

5. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–62.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting EGFR by Newer 1-(3,5-Bis((E)-4‑hydroxy-3-methoxystyryl)-1H-pyrazol-1-yl)-2-((substituted phenyl)amino)ethan-1-one Analogues for the Treatment of Cancer: Synthesis, In-vitro and In-silico Studies;Journal of Molecular Structure;2024-11

2. Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions;Molecular Cancer;2024-08-10

3. Breast Cancer Stem Cells and Tumor Heterogeneity: Characteristics and Therapeutic Strategies;Cancers;2024-07-07

4. Impact of PI3K pathway alterations on response to immune checkpoint inhibitors in HPV-negative head and neck squamous cell carcinoma;2024-07-04

5. NAD metabolism-related genes provide prognostic value and potential therapeutic insights for acute myeloid leukemia;Frontiers in Immunology;2024-06-20